IL319145A - נוגדנים חדשים אנטי- lilrb2ושימושים בהם - Google Patents
נוגדנים חדשים אנטי- lilrb2ושימושים בהםInfo
- Publication number
- IL319145A IL319145A IL319145A IL31914525A IL319145A IL 319145 A IL319145 A IL 319145A IL 319145 A IL319145 A IL 319145A IL 31914525 A IL31914525 A IL 31914525A IL 319145 A IL319145 A IL 319145A
- Authority
- IL
- Israel
- Prior art keywords
- novel anti
- lilrb2 antibodies
- lilrb2
- antibodies
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022114001 | 2022-08-22 | ||
| PCT/CN2023/110185 WO2024041315A1 (en) | 2022-08-22 | 2023-07-31 | Novel anti-lilrb2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319145A true IL319145A (he) | 2025-04-01 |
Family
ID=90012446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319145A IL319145A (he) | 2022-08-22 | 2023-07-31 | נוגדנים חדשים אנטי- lilrb2ושימושים בהם |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4577573A1 (he) |
| JP (1) | JP2025529878A (he) |
| KR (1) | KR20250093297A (he) |
| CN (1) | CN119768432A (he) |
| AU (1) | AU2023328075A1 (he) |
| CA (1) | CA3265647A1 (he) |
| IL (1) | IL319145A (he) |
| TW (1) | TW202423967A (he) |
| WO (1) | WO2024041315A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120173116B (zh) * | 2025-05-23 | 2025-09-09 | 上海宏成药业有限公司 | 抗lilrb2抗体及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| KR20200103706A (ko) * | 2017-12-22 | 2020-09-02 | 조운스 테라퓨틱스, 인크. | Lilrb2에 대한 항체 |
| TWI819024B (zh) * | 2018-07-09 | 2023-10-21 | 美商戊瑞治療有限公司 | 結合至ｉｌｔ４的抗體 |
| JP2022501428A (ja) * | 2018-09-17 | 2022-01-06 | アイカーン スクール オブ メディスン アット マウント シナイ | 抗ｌｉｌｒｂ２抗体およびその使用の方法 |
| AU2020351274A1 (en) * | 2019-09-20 | 2022-05-05 | Invectys SAS | Single-domain antibodies directed against LILRB2 |
| US20230068663A1 (en) * | 2020-02-05 | 2023-03-02 | The Board Of Regents Of The University Of Texas System | Novel lilrb2 antibodies and uses thereof |
| WO2022087188A1 (en) * | 2020-10-21 | 2022-04-28 | Immune-Onc Therapeutics, Inc. | Novel anti-lilrb2 antibodies and derivative products |
-
2023
- 2023-07-31 CN CN202380061297.XA patent/CN119768432A/zh active Pending
- 2023-07-31 EP EP23856405.8A patent/EP4577573A1/en active Pending
- 2023-07-31 IL IL319145A patent/IL319145A/he unknown
- 2023-07-31 KR KR1020257008740A patent/KR20250093297A/ko active Pending
- 2023-07-31 CA CA3265647A patent/CA3265647A1/en active Pending
- 2023-07-31 AU AU2023328075A patent/AU2023328075A1/en active Pending
- 2023-07-31 JP JP2025511564A patent/JP2025529878A/ja active Pending
- 2023-07-31 WO PCT/CN2023/110185 patent/WO2024041315A1/en not_active Ceased
- 2023-08-22 TW TW112131477A patent/TW202423967A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023328075A1 (en) | 2025-04-03 |
| CN119768432A (zh) | 2025-04-04 |
| KR20250093297A (ko) | 2025-06-24 |
| EP4577573A1 (en) | 2025-07-02 |
| TW202423967A (zh) | 2024-06-16 |
| JP2025529878A (ja) | 2025-09-09 |
| CA3265647A1 (en) | 2024-02-29 |
| WO2024041315A1 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308808A (he) | נוגדנים נגד ccr8 ושימושים שלהם | |
| EP4010378A4 (en) | ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF | |
| IL319931A (he) | נוגדנים אנטי- cd122 ושימושים בהם | |
| GB202017058D0 (en) | Antibodies and uses thereof | |
| GB2610467B (en) | Anti-CLL1 antibody and application thereof | |
| IL307267A (he) | נוגדני anti-cd122 ושימושיהם | |
| IL315265A (he) | נוגדנים מרובים ושימושים בהם | |
| IL307940A (he) | נוגדנים אנטי- adgre2ושימושים בהם | |
| IL315438A (he) | נוגדנים אנטי-cd3 חדשים ושימושים בהם | |
| IL308382A (he) | נוגדנים אנטי- cd276חדשים ושימושים בהם | |
| IL310662A (he) | נוגדנים אנטי- cd161ושימושים בהם | |
| TWI799855B (zh) | 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用 | |
| IL320586A (he) | נוגדן נגד trem2 ושימושים שלו | |
| EP4274851A4 (en) | MONOCLONAL ANTI-GPRC5D ANTIBODIES AND USES THEREOF | |
| IL317391A (he) | נוגדנים חדשים אנטי- lilrb4ושימושים בהם | |
| IL316510A (he) | נוגדן אנטי-b7h3 ושימושיו | |
| IL312584A (he) | נוגדני anti-vista ושימושים בהם | |
| EP4437000A4 (en) | ANTI-TREM2 ANTIBODY AND ITS USES | |
| IL307939A (he) | נוגדנים אנטי- clec12aושימושים בהם | |
| IL307233A (he) | נוגדנים אנטי- sema3aושימושים בהם | |
| IL319145A (he) | נוגדנים חדשים אנטי- lilrb2ושימושים בהם | |
| IL310810A (he) | נוגדנים אנטי- acvr2a ושימושים בהם | |
| IL308198A (he) | נוגדנים אנטי- il-27 ושימושים בהם | |
| IL317849A (he) | נוגדנים חד-שבטיים אנטי- slc34a2ושימושים בהם | |
| IL304412A (he) | נוגדנים כנגד cd112r ושימושים בהם |